|Last Price||Today's Change||52-Week Range||Trading Volume|
|0.75||-0.03 (-3.88%)||0.51 - 2.00||71.4 thousand (Below Avg)|
Market data as of 3:58PM 05/17/13. Quotes are delayed by at least 15 min.
The company expects to report revenues of approximately
Revenues for the full-year of 2012 are expected to be
“Revenues during the fourth quarter were softened by orders anticipated
to close during the period, which have shifted into our prospective
pipeline for 2013. Although we were successful in generating orders
during the fourth quarter, our revenues for the year were lower than our
prior guidance. I have been pleased with the progress we have made to
adapt our strategy to mitigate the competitive headwinds and pricing
pressure we are experiencing in the marketplace,” said
Mr. Cook continued,” For 2013 we expect revenues to be between
About Bacterin International Holdings
Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to achieve projected sales targets, the Company’s ability to successfully close transactions with stocking distributors, the Company’s ability to achieve projected market penetration despite industry wide pricing pressure, the Company’s ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of increased taxation, changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Bacterin Receives Compliance Notice from NYSE MKT
05/16/2013 9:00 AM ET
Bacterin Announces First Quarter 2013 Revenue of $8.6 Million
05/09/2013 4:00 PM ET